AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26613790 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg chromium supplements
Number of subjects: 60
Study 26613790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25752386 — intervention group
Group type: EXPERIMENTAL
Intervention: IG-IMRT
Number of subjects: 475
Study 25752386 — intervention group
Group type: COMPARATOR
Intervention: 3D-CRT
Number of subjects: 475
Study 23703468 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 181
Study 23703468 — intervention group
Group type: COMPARATOR
Intervention: Nystatin
Number of subjects: 181
Study 20578267 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline 10(‐5) M
Number of subjects: 12
Study 20578267 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 12
Study 18804136 — intervention group
Group type: EXPERIMENTAL
Intervention: CL184 (20IU/kg)
Number of subjects: 0
Study 18804136 — intervention group
Group type: EXPERIMENTAL
Intervention: CL184 (20 or 40IU/kg)
Number of subjects: 0
Study 18804136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16084757 — intervention group
Group type: EXPERIMENTAL
Intervention: WebCT group (n=39)
Number of subjects: 85
Study 16084757 — intervention group
Group type: COMPARATOR
Intervention: WWW group (n=46)
Number of subjects: 85
Study 12970656 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin-block appliance
Number of subjects: 174
Study 12970656 — intervention group
Group type: COMPARATOR
Intervention: Untreated (control group)
Number of subjects: 174
Study 10894101 — intervention group
Group type: EXPERIMENTAL
Intervention: Respocort (250-1000 microg per dose; cumulative dose 2000 microg)
Number of subjects: 18
Study 10894101 — intervention group
Group type: EXPERIMENTAL
Intervention: Becloforte (250-1000 microg per dose; cumulative dose 2000 microg)
Number of subjects: 18
Study 10894101 — intervention group
Group type: COMPARATOR
Intervention: Control mixture (containing surfactant and CFC propellants)
Number of subjects: 18
Study 8927657 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone-treated patients
Number of subjects: 12
Study 8927657 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 12
Study 2066844 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (20 mg/kg per day, three times a day for 10 days)
Number of subjects: 55
Study 2066844 — intervention group
Group type: COMPARATOR
Intervention: Penicillin plus rifampin (benzathine penicillin intramuscularly and rifampin 20 mg/kg per day, twice a day for 4 days)
Number of subjects: 55
Study 2066844 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (including crossover patients)
Number of subjects: 55
Study 2066844 — intervention group
Group type: COMPARATOR
Intervention: Penicillin plus rifampin (including crossover patients)
Number of subjects: 55
Study 7034680 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous dose of gentamicin sulfate and clindamycin phosphate
Number of subjects: 0
Study 7034680 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotic prophylaxis)
Number of subjects: 0
Study 30247401 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing
Number of subjects: 240
Study 30247401 — intervention group
Group type: COMPARATOR
Intervention: External fixation
Number of subjects: 240
Study 26861051 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine granules (MG) 1.5 g once daily
Number of subjects: 562
Study 26861051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 562
Study 26861051 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine granules (MG)
Number of subjects: 562
Study 26861051 — intervention group
Group type: COMPARATOR
Intervention: Mesalamine granules (MG) and Placebo
Number of subjects: 562
Study 25511452 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured use of a pedometer and handbook with support from a practice nurse trained in behaviour change techniques (BCTs)
Number of subjects: 43
Study 25511452 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured use of a pedometer and handbook without support from a practice nurse trained in behaviour change techniques (BCTs)
Number of subjects: 43
Study 25511452 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change techniques (BCTs) reported to have the most impact
Number of subjects: 43
Study 25511452 — intervention group
Group type: EXPERIMENTAL
Intervention: Rewards
Number of subjects: 43
Study 23297520 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind, placebo controlled food challenge test
Number of subjects: 179
Study 23297520 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE and skin prick tests
Number of subjects: 179
Study 20427960 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention strategies for cardiorenal syndromes, including identification and amelioration of precipitating factors, optimal management of chronic heart and kidney diseases, and multimodality therapies for end-organ protection.
Number of subjects: 0
Study 18483650 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based obesity prevention intervention including nutrition education and promotion of physical activity.
Number of subjects: 1760
Study 18483650 — intervention group
Group type: COMPARATOR
Intervention: Control group (similar school in Quillota).
Number of subjects: 1760
Study 18483650 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based obesity prevention intervention.
Number of subjects: 1760
Study 18483650 — intervention group
Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 1760
Study 15872223 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplified enzyme immunoassay (EIA) with negative gray zone testing
Number of subjects: 1003
Study 15872223 — intervention group
Group type: COMPARATOR
Intervention: Cobas PCR
Number of subjects: 1003
Study 11902268 — intervention group
Group type: EXPERIMENTAL
Intervention: HME changed every 24 hrs
Number of subjects: 155
Study 11902268 — intervention group
Group type: COMPARATOR
Intervention: HME changed every 7 days
Number of subjects: 155
Study 10511423 — intervention group
Group type: EXPERIMENTAL
Intervention: Scrambled-sentences task with illness terms
Number of subjects: 3355
Study 10511423 — intervention group
Group type: COMPARATOR
Intervention: Scrambled-sentences task with neutral terms
Number of subjects: 3355
Study 10511423 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimates of likelihood of catastrophic illness
Number of subjects: 3355
Study 10511423 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimates of likelihood of minor illnesses
Number of subjects: 3355
Study 10511423 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-esteem
Number of subjects: 3355
Study 7837862 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-osmolarity ORS (224 mmol/L)
Number of subjects: 447
Study 7837862 — intervention group
Group type: COMPARATOR
Intervention: Standard ORS (311 mmol/L)
Number of subjects: 447
Study 2351319 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (100 mg/m2 iv bolus) and 5-fluorouracil (1000 mg/m2/day for 4 days) with allopurinol (900 mg orally, starting 5 days before 5-fluorouracil)
Number of subjects: 52
Study 2351319 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and 5-fluorouracil without allopurinol
Number of subjects: 52
Study 351827 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine (Kiel) bone interbody fusion
Number of subjects: 20
Study 351827 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone interbody fusion
Number of subjects: 20
Study 30188331 — intervention group
Group type: EXPERIMENTAL
Intervention: Equol producers
Number of subjects: 58
Study 30188331 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher consumption of foods such as meat, fish, soy, vegetables, and Japanese snacks
Number of subjects: 58
Study 30188331 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of Ramen and smoking
Number of subjects: 58
Study 27957644 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind bedside technique (BST)
Number of subjects: 180
Study 27957644 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopically guided technique (FGT)
Number of subjects: 180
Study 26342674 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative FOLFOX chemotherapy
Number of subjects: 82
Study 26342674 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 82
Study 22883712 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin (dual treatment) for seven days
Number of subjects: 70
Study 22883712 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (monotherapy) for seven days
Number of subjects: 70
Study 21872933 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment (ET) - laser photocoagulation at high-risk prethreshold ROP
Number of subjects: 401
Study 21872933 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (CM) - treatment only if threshold ROP developed
Number of subjects: 401
Study 21872933 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ET and CM
Number of subjects: 401
Study 20076870 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy and pelvic reconstruction floor with mesh (n=15)
Number of subjects: 31
Study 20076870 — intervention group
Group type: COMPARATOR
Intervention: Hysteropexy and pelvic reconstruction floor with mesh (n=16)
Number of subjects: 31
Study 17983937 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitizers
Number of subjects: 0
Study 15566709 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped information regarding consent for surgery
Number of subjects: 48
Study 15566709 — intervention group
Group type: COMPARATOR
Intervention: Verbal information regarding consent for surgery
Number of subjects: 48
Study 11172346 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG(40kd) IFN alpha‐2a 45 microg once weekly
Number of subjects: 159
Study 11172346 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG(40kd) IFN alpha‐2a 90 microg once weekly
Number of subjects: 159
Study 11172346 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG(40kd) IFN alpha‐2a 180 microg once weekly
Number of subjects: 159
Study 11172346 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG(40kd) IFN alpha‐2a 270 microg once weekly
Number of subjects: 159
Study 11172346 — intervention group
Group type: COMPARATOR
Intervention: IFN alpha‐2a 3 MIU 3 times weekly
Number of subjects: 159
Study 9666761 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg twice daily
Number of subjects: 293
Study 9666761 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin 5 mg three times daily
Number of subjects: 293
Study 9666761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 293
Study 7645930 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioimmunoassisted follow-up plan (Group 1)
Number of subjects: 485
Study 7645930 — intervention group
Group type: COMPARATOR
Intervention: Traditional examinations (Group 2)
Number of subjects: 485
Study 7645930 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoscintigraphy
Number of subjects: 485
Study 7645930 — intervention group
Group type: EXPERIMENTAL
Intervention: RIGE
Number of subjects: 485
Study 7645930 — intervention group
Group type: EXPERIMENTAL
Intervention: IORIL
Number of subjects: 485
Study 2529059 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic atrial natriuretic factor (ANF) at 1 pmol/kg/min
Number of subjects: 8
Study 2529059 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic atrial natriuretic factor (ANF) at 2 pmol/kg/min
Number of subjects: 8
Study 2529059 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (hemaccel)
Number of subjects: 8
Study 794996 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel (0.5%)
Number of subjects: 10
Study 794996 — intervention group
Group type: COMPARATOR
Intervention: Commercial toothpaste with claimed chlorhexidine content
Number of subjects: 10
Study 794996 — intervention group
Group type: COMPARATOR
Intervention: Traditional toothpastes (2 types)
Number of subjects: 10
Study 31292906 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 19
Study 31292906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 28060534 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical repair of stable ramp lesions
Number of subjects: 91
Study 28060534 — intervention group
Group type: COMPARATOR
Intervention: Abrasion and trephination of stable ramp lesions
Number of subjects: 91
Study 25529005 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 78
Study 25529005 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide
Number of subjects: 78
Study 25529005 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 78
Study 23111547 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) prevention system
Number of subjects: 0
Study 23111547 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 21796066 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 5 mg (single intravenous infusion)
Number of subjects: 110
Study 21796066 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene 60 mg (daily oral for 6 months)
Number of subjects: 110
Study 19250151 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin Choice decision aid
Number of subjects: 98
Study 19250151 — intervention group
Group type: COMPARATOR
Intervention: Patient pamphlet about dyslipidaemia
Number of subjects: 98
Study 16717032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran (2 x 36 mg)
Number of subjects: 75
Study 16717032 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin/warfarin
Number of subjects: 75
Study 16717032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran (2 x 24 mg)
Number of subjects: 75
Study 16717032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 12870820 — intervention group
Group type: EXPERIMENTAL
Intervention: Unimpaired speakers of Italian
Number of subjects: 0
Study 12870820 — intervention group
Group type: COMPARATOR
Intervention: Alzheimer's Disease (AD) patients
Number of subjects: 0
Study 10836333 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized recombinant human deoxyribonuclease (DNase)
Number of subjects: 52
Study 10836333 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 52
Study 8943829 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust with the particle trap at the tail pipe
Number of subjects: 12
Study 8943829 — intervention group
Group type: COMPARATOR
Intervention: Unfiltered diesel exhaust
Number of subjects: 12
Study 8943829 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 12
Study 1917073 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration frequencies of 31.5‐63 Hz at 10 m/s2 (rms)
Number of subjects: 18
Study 1917073 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration frequencies of 250‐500 Hz at 10 m/s2 (rms)
Number of subjects: 18
Study 1917073 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration frequencies of 31.5‐63 Hz at 50 m/s2 (rms)
Number of subjects: 18
Study 1917073 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration frequency of 500 Hz at 50 m/s2 (rms)
Number of subjects: 18
Study 7050710 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (0.5 g given three times a day)
Number of subjects: 1303
Study 7050710 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulants
Number of subjects: 1303
Study 7050710 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1303
Study 3158636 — intervention group
Group type: EXPERIMENTAL
Intervention: Maneuver E (feedback with visual feedback of pleural and abdominal pressure)
Number of subjects: 35
Study 3158636 — intervention group
Group type: EXPERIMENTAL
Intervention: Maneuvers A, B, and D
Number of subjects: 35
Study 3158636 — intervention group
Group type: EXPERIMENTAL
Intervention: Maneuver C
Number of subjects: 35
Study 3158636 — intervention group
Group type: COMPARATOR
Intervention: All maneuvers
Number of subjects: 35
Study 3158636 — intervention group
Group type: EXPERIMENTAL
Intervention: Maneuvers A and B
Number of subjects: 35
Study 3158636 — intervention group
Group type: EXPERIMENTAL
Intervention: Maneuver D and E
Number of subjects: 35
Study 31601539 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation
Number of subjects: 0
Study 31601539 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study 30390203 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg/Valsartan 160 mg (A/V)
Number of subjects: 137
Study 30390203 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg/Valsartan 160 mg (N/V)
Number of subjects: 137
Study 26930583 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg artesunate and 135 mg amodiaquine fixed dose formulation
Number of subjects: 14
Study 26930583 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 14
Study 23903900 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0.2 % ropivacaine at 4 ml/h with a bolus of 0 ml
Number of subjects: 99
Study 23903900 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0.2 % ropivacaine at 0 ml/h with a bolus of 4 ml
Number of subjects: 99
Study 23903900 — intervention group
Group type: COMPARATOR
Intervention: IV-PCA
Number of subjects: 99
Study 23903900 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 99
Study 22343599 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS(MD1)
Number of subjects: 175
Study 22343599 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS(MD2)
Number of subjects: 175
Study 22343599 — intervention group
Group type: EXPERIMENTAL
Intervention: WES(MD1)
Number of subjects: 175
Study 22343599 — intervention group
Group type: EXPERIMENTAL
Intervention: WES(MD2)
Number of subjects: 175
Study 22343599 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS(Pt)
Number of subjects: 175
Study 22343599 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS(Plast1)
Number of subjects: 175
Study 22343599 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS(Plast2)
Number of subjects: 175
Study 22343599 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS(MD) and VAS(Plast)
Number of subjects: 175
Study 22343599 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS(Pt) and WES(MD)
Number of subjects: 175
Study 22343599 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS(MD) and WES(MD)
Number of subjects: 175
Study 22343599 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS(MD1) and VAS(MD2)
Number of subjects: 175
Study 22343599 — intervention group
Group type: EXPERIMENTAL
Intervention: WES(MD1) and WES(MD2)
Number of subjects: 175
Study 22343599 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS(Plast1) and VAS(Plast2)
Number of subjects: 175
Study 22343599 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS(Pt) and VAS(Plast)
Number of subjects: 175
Study 22343599 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS(Pt) and VAS(MD)
Number of subjects: 175
Study 22343599 — intervention group
Group type: EXPERIMENTAL
Intervention: WES(MD) and VAS(Plast)
Number of subjects: 175
Study 20336047 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamberin in combined treatment
Number of subjects: 138
Study 18771056 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-free injection device (NFID)
Number of subjects: 58
Study 18771056 — intervention group
Group type: COMPARATOR
Intervention: Standard 27-gauge half-inch needle/syringe (NS)
Number of subjects: 58
Study 16340384 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) at 500 mg twice daily for 2 months, then increased to 1000 mg twice daily for 4 months
Number of subjects: 22
Study 16340384 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 22
Study 12679951 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic nasopancreatic drainage (ENPD)
Number of subjects: 14
Study 10479911 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 121
Study 10479911 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (ChT)
Number of subjects: 121
Study 8792955 — intervention group
Group type: EXPERIMENTAL
Intervention: Dornase
Number of subjects: 0
Study 8792955 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 1960363 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric psychiatry consultation and follow-up at least once per week for 8 weeks
Number of subjects: 80
Study 1960363 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 80
Study 6754510 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolciclate 1% cream and lotion applied twice a day for about 3 weeks
Number of subjects: 278
Study 6754510 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole 1% cream and lotion applied twice a day for about 3 weeks
Number of subjects: 278
Study 30803305 — intervention group
Group type: COMPARATOR
Intervention: AbobotulinumtoxinA 15 U/kg/leg
Number of subjects: 10
Study 30803305 — intervention group
Group type: COMPARATOR
Intervention: AbobotulinumtoxinA 10 U/kg/leg
Number of subjects: 10
Study 30803305 — intervention group
Group type: COMPARATOR
Intervention: AbobotulinumtoxinA
Number of subjects: 10
Study 30803305 — intervention group
Group type: COMPARATOR
Intervention: OnabotulinumtoxinA 4 U/kg/leg
Number of subjects: 10
Study 30803305 — intervention group
Group type: COMPARATOR
Intervention: OnabotulinumtoxinA 4 U/kg/leg + casting
Number of subjects: 10
Study 30803305 — intervention group
Group type: COMPARATOR
Intervention: OnabotulinumtoxinA 8 U/kg
Number of subjects: 10
Study 28672098 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Budesonide 1000 μg/dose
Number of subjects: 49
Study 28672098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 27269956 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibudilast (20 mg twice daily followed by 50 mg twice daily)
Number of subjects: 0
Study 27269956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25462610 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance Based Financing (PBF)
Number of subjects: 4916